Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824375 | 0.77 | NPC1 (0.69) | NPC1RAB9AMAPTPSMB8TP53 | |
| SCHEMBL29531707 | 0.77 | NPC1 (0.69) | NPC1RAB9AMAPTPSMB8TP53 | |
| SCHEMBL28409963 | 0.73 | NPC1 (0.50) | NPC1RAB9AMAPTPSMB8TP53 | |
| SCHEMBL6445389 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTPSMB8TP53 | |
| SCHEMBL9542349 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTPSMB8TP53 | |
| SCHEMBL430870 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTPSMB8TP53 | |
| SCHEMBL474946 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTPSMB8TP53 | |
| SCHEMBL22190326 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTPSMB8TP53 | |
| SCHEMBL129661 | 0.71 | MAPT (0.59) | NPC1RAB9AMAPTPSMB8TP53 | |
| SCHEMBL6445384 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTPSMB8TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | claimed |
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | claimed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | claimed |
| EP-1730125-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | claimed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2000034251-A1 | A METHOD FOR QUANTITATIVE DETERMINATION OF AMINO ACIDS | SMITHKLINE BEECHAM CORPORATION (GB) | 2000-06-15 | — | — | WO | claimed |
| EP-0749419-A1 | OXIME DERIVATIVES AND THEIR USE AS PESTICIDES | BAYER AG (DE) | 1996-12-27 | — | — | EP | claimed |
| WO-1995024383-A1 | OXIME DERIVATIVES AND THEIR USE AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1995-09-14 | — | — | WO | claimed |
| US-5243033-A | Dyeing or printing of cellulose | CIBA-GEIGY CORPORATION (US) | 1993-09-07 | — | — | US | claimed |
| US-5232462-A | Lightfast, colorfast | CIBA-GEIGY CORPORATION (US) | 1993-08-03 | — | — | US | claimed |
| US-4843148-A | FIBER-REACTIVE DYE | CIBA-GEIGY CORPORATION (US) | 1989-06-27 | — | — | US | claimed |
| US-4841049-A | FOR CELLULOSIC FIBERS; BRIGHT BLUE COLORS; WET- AND LIGHTFAST | CIBA-GEIGY CORPORATION (US) | 1989-06-20 | — | — | US | claimed |
| EP-0041040-A1 | Sulphofree basic azo compounds in metal complex form, in metal-free form and method for preparing the same | SANDOZ AG (CH) | 1981-12-02 | — | — | EP | claimed |
| WO-2024043261-A1 | AZO COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME | 日本化薬株式会社 | 2024-02-29 | — | — | WO | disclosed |
| CN-114026199-B | Polarized light emitting film, polarized light emitting panel and display device containing water-soluble coumarin compound or salt thereof | 日本化药株式会社 | 2023-12-26 | — | — | CN | disclosed |
| US-11802208-B2 | Stilbene-based compound or salt thereof, and polarizing film, polarizing plate, and display device | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2023-10-31 | — | — | US | disclosed |
| US-4293691-A | Method for preparing magenta couplers having thioether groups | FUJI PHOTO FILM CO., LTD. (JP) | 1981-10-06 | — | — | US | disclosed |
| US-4146396-A | TWO EQUIVALENT COUPLER | FUJI PHOTO FILM CO., LTD. (JP) | 1979-03-27 | — | — | US | disclosed |
| US-4076533-A | MAGENTA DYE | FUJI PHOTO FILM CO., LTD. (JA) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | DNPEP, MME, ANPEP | NPC1 1518/4885RAB9A 2645/4885MAPT 249/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | NPC1 1518/4885RAB9A 2645/4885MAPT 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.